Detalhe da pesquisa
1.
Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model.
Cell
; 152(1-2): 340-51, 2013 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-23332765
2.
Cells exhibiting strong p16INK4a promoter activation in vivo display features of senescence.
Proc Natl Acad Sci U S A
; 116(7): 2603-2611, 2019 02 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30683717
3.
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.
Int J Cancer
; 148(10): 2557-2570, 2021 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33348420
4.
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Breast Cancer Res Treat
; 180(3): 635-646, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32130619
5.
Circular RNAs are abundant, conserved, and associated with ALU repeats.
RNA
; 19(2): 141-57, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23249747
6.
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
Cancer Res
; 83(1): 141-157, 2023 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36346366
7.
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.
Cancer Chemother Pharmacol
; 87(5): 689-700, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33595690
8.
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
J Immunother Cancer
; 8(2)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33004541
9.
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
Cancer Discov
; 8(2): 216-233, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29101163
10.
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Oncotarget
; 8(26): 42343-42358, 2017 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28418845
11.
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.
Sci Transl Med
; 9(387)2017 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28446688
12.
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.
Mol Cancer Ther
; 15(5): 783-93, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26826116
13.
Defining the toxicology of aging.
Trends Mol Med
; 20(7): 375-84, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24880613
14.
p16INK4a reporter mice reveal age-promoting effects of environmental toxicants.
J Clin Invest
; 124(1): 169-73, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24334456